Embed Size (px)
Citation preview
International Pancreatic Cancer Forum –
Global Trends in FOLFIRINOX treatment for Pancreatic
Cancer
國際胰臟癌論壇 Date: 27th July, 2019 13:00-17:20
Venue: Conference Rm 401, 4F, Hall 1, Taipei Nangang Exhibition Hall
日期：7/27(六)下午13:30~17:20
地點：南港展覽館4樓401會議室(地址：台北市南港區經貿二路1號4樓)
Organizer: Taiwan Pancreas Society, Taiwan Oncology Society, SynCore Biotechnology, Taiwan Bio Industry
Organization
主辦單位:台灣胰臟醫學會, 中華民國癌症醫學會, 杏國新藥股份有限公司
Time Topic Speaker
13:00-13:30 Registration
13:30-13:50
Opening Remarks
Dr. Shou-Mei Wu, Director General of Taiwan Food and Drug
Administration
Dr. Li-Tzong Chen, President of Taiwan Oncology Society
Dr. Ta-Sen Yeh, President of Taiwan Pancreas Society
Dr. Muh-Hwan Su, General manager of SynCore Biotechnology
Session Moderator: Dr. Ta-Sen Yeh, President of Taiwan Pancreas Society
13:50-14:20
The experience of mFOLFIRINOX
for patients with pancreatic cancer
Dr. Li Yuan Bai
Director, Division of Hematology and Oncology, China Medical
University Hospital, Taiwan
14:20-14:50
The Korea experience of
FOLFIRINOX in pancreatic cancer
Dr. Hong Jae Chon
Associate Professor, Medical Oncology, Department of Internal
Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-
Do, South Korea
14:50-15:10 Coffee Break
Session Moderator: Dr. Li-Tzong Chen, President of Taiwan Oncology Society
15:10-15:40
The U.S. experience of
FOLFIRINOX in pancreatic cancer
Dr. Philip Agop Philip
Karmanos Cancer Institute, Wayne State University, Leader, GI and
Neuroendocrine Oncology, Vice President of Medical Affairs USA
15:40-16:10
The Hungary experience of
FOLFIRINOX in pancreatic cancer
Dr. Zsuzsanna Pápai
Professor, Department of Oncology, Magyar Honvédség Egészségügyi
Központ, Budapest, Hungary
16:10-16:40
The France experience of
FOLFIRINOX in pancreatic cancer
Dr. Jean-Philippe Metges
Professor, CHRU Brest-Hôpital Morvan Brest, France
16:40-17:10
Panel Discussion
Dr. Li Yuan Bai, Director, China Medical University Hospital,Taiwan
Dr. Hong Jae Chon, Associate Professor, CHA Bundang Medical
Centera, South Korea
Dr. Jean-Philippe Metges, Professor, CHRU Brest-Hôpital Morvan
Dr. Philip Agop Philip, Vice President of Medical Affairs USA
Dr. Zsuzsanna Pápai, Professor, Magyar Honvédség Egészségügyi
Központ, Budapest, Hungary.
Dr. Li-Tzong Chen, President of Taiwan Oncology Society
Dr. Ta-Sen Yeh, President of Taiwan Pancreas Society
Dr. Muh-Hwan Su, General Manager, SynCore Biotechnology
17:10-17:20 Closing Remarks Dr. Muh-Hwan Su, General manager of SynCore Biotechnology
學會教育積分：(申請中)
台灣外科醫學會
台灣消化系內視鏡醫學會
台灣消化系醫學會
台灣內視鏡外科醫學會
中華民國癌症醫學會
不收費需事先線上報名
報名連結如下 Chinese: https://bit.ly/2KwOUSR
English: https://bit.ly/2N7QnBg
報名電話：02-2760-3688*2854蕭小姐
報名傳真：02-2763-9287
Email Add：[email protected]
Curriculum vitae
Name: Li-Yuan Bai, M.D., M.M.S., Ph.D.
E-mail: [email protected]
Current
Position:
Feb. 2017: Professor, China Medical University
Jan. 2018: Director, Division of Hematology and Oncology, China Medical University
Hospital, Taichung, Taiwan
Jul. 2018: Deputy Director, Clinical Trial Center, China Medical University Hospital
Education and
Board:
Sep. 1987 – Jun. 1994: School of Medicine, National Yang-Ming University, Taipei, Taiwan
Mar. 1997: Certification of Educational Commission for Foreign Medical Graduates, USA
Oct. 2001: Certified Doctor of Internal Medicine
Nov. 2003: Certified Doctor of Medical Oncology
Feb. 2004: Member of Taiwan Academy of Hospice Palliative Medicine
Nov. 2004: Certified Doctor of Hematology
Jul. 2007: Master of Medical Science, Graduate Institute of Medical Science, China Medical
University, Taichung, Taiwan
Jun. 2011: Ph.D., Graduate Institute of Clinical Medical Science, China Medical University,
Taichung, Taiwan
Previous
Employments:
Jun. 1998 - Dec. 2004: Resident doctor, Department of Medicine, Taipei Veterans General
Hospital (VGH), Taipei, Taiwan
Dec. 2004 – Jul. 2005: Visiting staff, Department of Medicine, Yilan Hospital
Mar. 2008 – May. 2009: Visiting scholar at College of Pharmacy, The Ohio State University,
Columbus, OH, USA
Aug. 2005 – present : Attending Physician, Division of Hematology and Oncology, China
Medical University Hospital, Taichung, Taiwan
Publications (after 2016)
1. Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa
T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda
M, Tanimoto M, Chen LT, Boku N. Exploratory subgroup analysis of patients with prior trastuzumab use in
the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of
nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer 2019 (accepted)
2. Cheng-Wen Lin, Hsien-Kuo Chin, Shou-Lun Li, Chang-Fang Chiu, Jing-Gung Chung, Zi-Yin Lin, Chia-
Yung-Wu, Ying-Chen Liu, Yung-Ting Hsiao, Chia-Hsien Feng, Li-Yuan Bai*, and Jing-Ru Weng*. Ursolic
acid induces apoptosis and autophagy in oral cancer cells. Environ Toxicol 2019 (accepted)
3. Chia-Yu Chen, Chang-Fang Chiu, Li-Yuan Bai*. Treatment of pembrolizumab-induced cutaneous lesions
with ruxolitinib. Eur J Cancer 2019 Apr 12;113:69-71.
4. Weng JR, Bai LY, Chiu SJ, Chiu CF, Lin WY, Hu JL, Shieh TM. Divaricoside Exerts Antitumor Effects, in
Part, by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells. Comput Struct Biotechnol J
2019 Jan 26;17:151-159.
5. Jing-Ru Weng, Ching-Shih Chen, Chang-Fang Chiu Chiu, Jing-Lan Hu, Chia-Hsien Feng, Chiung-Yao
Huang, Li-Yuan Bai*, Jyh-Horng Sheu*. A 9,11-secosterol from soft coral induces apoptosis and autophagy
in MCF-7 breast cancer cells. Mar Drugs 2018 Jul 17:16(7).pii:E238.
6. Lien MY, Chou CH, Lin CC, Bai LY, Chiu CF, Yeh SP, Ho MW. Epidemiology and risk factors for invasive
fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective
cohort study. PLoS One 2018 Jun 8;13(6):e0197851.
7. Kuo CY, Wang PN, Hwang WL, Tzeng CH, Bai LY, Tang JL, Chang MC, Lin SF, Chen TY, Chen YC, Tan
TD, Hsieh CY, Lin C, Lai C, Miljkovic D, Chang CS*. Safety and efficacy of nilotinib in routine clinical
practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or
intolerance to imatinib: results from the NOVEL study. Ther Adv Hematol 2018 Mar;9(3):65-78.
8. Weng JR*, Bai LY, Ko HH, Tsai YT. Cyclocommunol induces apoptosis in human oral squamous cell
carcinoma partially through a Mcl-1-dependent mechanism. Phytomedicine 2018 Jan 15;39:25-32.
9. Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-
Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao
Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi,
Jae Yong Cho,Masahiro Tsuda, Li-Tzong Chen. Nivolumab in patients with advanced gastric or gastro-
oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
(ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.
2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5.
10. Weng JR*, Bai LY, Lin WY. Identification of a Triterpenoid as a Novel PPARγ Activator Derived from
Formosan Plants. Phytother Res. 2017 Nov;31(11):1722-1730. doi: 10.1002/ptr.5900.
11. Bai LY, Chiu CF, Chiu SJ, Chu PC, Weng JR. FTY720 induces autophagy-associated apoptosis in human
oral squamous carcinoma cells, in part, through a reactive oxygen species/Mcl-1-dependent mechanism. Sci
Rep 2017 Jul 17;7(1):5600. doi: 10.1038/s41598-017-06047-9.
12. Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR*. OSU-A9 inhibits pancreatic
cancer cell lines by modulating p38-JAK-STAT3 signaling. Oncotarget 2017 Apr 25;8(17):29233-29246.
doi: 10.18632/oncotarget.16450
13. Weng JR*, Bai LY, Lin WY, Chiu CF, Chen YC, Chao SW, Feng CH. A Flavone Constituent from
Myoporum bontioides Induces M-Phase Cell Cycle Arrest of MCF-7 Breast Cancer Cells. Molecules 2017
Mar 15;22(3). pii: E472.
14. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Tse-Yen Yang, Aaron M. Sargeant,
Li-Yuan Bai*. Palliative gastrectomy prolongs survival of metastatic gastric cancer patients with normal
preoperative CEA or CA19-9 values: a retrospective cohort study. Gastroenterol Res Pract
2016;2016:6846027.
15. Chiu CF, Weng JR, Jadhav A, Wu CY, Sargeant AM, Bai LY*. T315 decreases acute myeloid leukemia cell
viability through a combination of apoptosis induction and autophagic cell death. Int J Mol Sci 2016 Aug
15;17(8). pii: E1337.
16. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Aaron M. Sargeant, Su-Peng Yeh, Li-
Yuan Bai*. The role of adjuvant chemotherapy for patients with stage II and stage III gastric
adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. Springerplus 2016
Jun 16;5(1):728.
17. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, Chiu SJ, Chiang JH, Weng JR*. Pharmacological
exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing
strategy. Sci Rep. 2016 Jun 9;6:27540. doi: 10.1038/srep27540.
18. Bai LY, Chiu CF, Chu PC, Lin WY, Chiu SJ, Weng JR*. A triterpenoid from wild bitter gourd inhibits breast
cancer cells. Sci Rep. 2016 Mar 1;6:22419. doi: 10.1038/ srep22419.
Curriculum Vitae
▪ Name Hong Jae Chon, MD, PhD
▪ Address Associate Professor,
Medical Oncology, Department of Internal Medicine,
CHA Bundang Medical Center, CHA University,
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13496, Korea
▪ Contact Phone: 82-31-780-3737 E-mail: [email protected] or [email protected]
▪ Education
1998.3.-2005.2. MD, Yonsei University College of Medicine, Seoul, Korea.
2008.3.-2018.8. PhD, Yonsei Graduate School, Seoul, College of Medicine, Korea,
Supervised by Professor Joong Bae Ahn
Doctoral thesis: “Combination immunotherapy of oncolytic virus and immune checkpoint inhibitor in
renal cell carcinoma”
▪ Professional Experiences
2005.3.-2006.2. Rotating internship, Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea
2006.3.-2010.2. Residency in Internal Medicine, Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea
2013.5.-2014.2 Clinical Fellow, Division of Medical Oncology, Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea
2014.3-2015.8 Clinical Research Professor, Division of Medical Oncology, Severance Hospital, Yonsei
University College of Medicine, Seoul, Korea 2015.9.- Assistant Professor, Medical Oncology,
CHA Bundang Medical Center, CHA University, Seongnam, Korea
2016.1- Co-Director, Laboratory of Tumor Vasculature and Microenvironment, CHA University,
Pangyo, Seongnam, Korea (https://sites.google.com/view/ltio)
2019.3.- Associate Professor, Medical Oncology,
CHA Bundang Medical Center, CHA University, Seongnam, Korea
▪ Full list of Publications
1. Kim C*, Chon HJ*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized
phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. European
Journal of Cancer 2018 (IF 7.191) (*Co-first author)
2. Chon HJ*, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH,
Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the
efficacy of immune checkpoint blockade. Clinical Cancer Research 2019 (IF 10.199)
3. Chon HJ*, Kim C*, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M,
Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric
Cancer. Gastric Cancer 2018 (IF 5.454) (E-pub)
4. Kim C, Kim WR, Kim KY, Chon H, Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB. Predictive
Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. Clinical Colorectal
Cancer 2018 (IF 4.507);17(3):e513-e518.
5. Kim HS, Chon HJ, Kim HK, Shin SJ, Wacheck Volker, Gruver AM, Kim JS, Rha SY, Chung HC. MET
in gastric cancer with liver metastasis: The relationship between MET amplification and Met
overexpression in primary stomach tumors and liver metastasis. Journal of SUGGICAL ONCOLOGY
2018 (IF 2.886)
6. Kim C*, Lee C*, Chon HJ*, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY.
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in
HER2-positive gastric cancer. Oncotarget 2017 (IF 5.168), 8(69):113494-501 (*Co-first author)
7. Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon, DS,
Jeung HC. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. Cancer Res
Treat 2017 (IF 3.230)
8. Chon HJ*, Hyung WJ*, Kim, C, Park SH, Kim JH, Park CH, Ahn JB, Kim HK, Chung HC, Rha SY, Noh
SH, Jeung HC. Different implication of gastric signet ring cell carcinoma. Annals of Surgery 2017 (IF
9.203)
9. Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee
SJ, Kim HS. Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-
Institutional Experience with a Rare Sarcoma. APMIS 2017 (IF 1.933), 125:223-229
10. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS,
Ahn JB, Chung HC, Noh SH, Rha SYm Kim SH, Kim HS. Prognostic Implications of PD-L1 Expression
in Patients with Soft Tissue Sarcoma. BMC Cancer 2016 (IF 3.265), 16:434
11. Lim SM, Kim YN, Park KH, Kang BD, Chon HJ, Kim C, Kim JH, Rha SY. Bone alkaline phosphatase as
a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 2016 (IF 3.265), 16:385
12. Kim C, Yang H, Park I, Chon HJ, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY. Rho GTPase RhoJ is
associated with gastric cancer progression and metastasis. Journal of Cancer 2016 (IF 3.609), 7(11):1550-
1556
13. Chon HJ*, Kim HR*, Shin E, Kim C, Heo SJ, Lee C, Park JK, Noh SH, Chung HC, Rha SY. The
Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients.
Annals of Surgical Oncology 2015 (IF 3.943), 22(12):3938-45
14. Park JS, Jeung HC, Rha SY, Ahn JB, Kang BD, Chon HJ, Hong MH, Lim ST, Yang WI, Nam CM,
Chung HC. M. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast
cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol 2014 (IF 2.808)
15. Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. Prediction of metachronous
multiple primary cancers following the curative resection of gastric cancer. BMC Cancer 2013 (IF 3.319),
13(1):394.
16. Chon HJ, SY Rha, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HCl. Salvage
chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with
advanced gastric cancer. Cancer Chemotherapy and Pharmacology (IF 2.769) October 2011, Volume 68,
Issue 4, pp 991-999,
17. Hong MH, Koo HM, Choi J, Ahn JR, Chon HJ, Kim C, Lee ST. A case of nephrogenic systemic fibrosis
after gadolinium-based contrast agent injection. Korean Journal of Medicine 2010, 78(1):127-131.
18. Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, Ahn JR, Noh SH, Chung HC, Jeung HC.
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined
analysis of two phase II trials. Cancer Research and Treatment 2009 (IF 2.975), 41(4):196-204.
19. Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Clinical
value of ezrin expression in primary osteosarcoma. Cancer Research and Treatment 2009 (IF 2.975),
41(3):138-144.
20. Ahn JR, Hong M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh
SH, Rha SY. Prognosis of pN3 stage gastric cancer. Cancer Research and Treatment 2009 (IF 2.975),
41(2):73-79.
21. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment
outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center
experience in Korea. Cancer Research and Treatment 2009 (IF 2.975), 41(2):67-72.
▪ Presentations
1. Oral presentation on “Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously
treated patients with advanced gastric cancer” (Korean Association for Clinical Oncology Meeting, 2010)
2. Oral presentation on “BIM deletion polymorphism as a biomarker in advanced gastric cancer” (Japanese
Gastric Cancer Association for Clinical Oncology Meeting, Osaka, Japan, 2013)
3. Oral presentation on “A phase IB/II Trial of FGF trap and paclitaxel combination treatment in patient with
advanced gastric cancer” (KCSG Methodology Workshop, Seoul, Korea, 2014) Award for outstanding
presentation
4. Oral presentation on “The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected
Gastric Cancer Patients” (Global Academic Program 2014 Conference)
6. Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer (ASCO
Annual Meeting, Chicago, United States, 2015)
7. Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with
recurrent/metastatic gastric cancer (ASCO Annual Meeting, Chicago, United States, 2016)
8. Adjuvant chemotherapy in gastric cancer (The 17th Clinical Trial Education Workshop, Seoul, Korea, 2017)
9. Adjuvant Treatment of pancreatic cancer (KCSG, Hepatobiliary & pancreatic cancer symposium, Seoul,
Korea, 2017)
10. STING agonist modulates tumor immune microenvironment of NSCLC to potentiate the efficacy of PD-1
immune checkpoint blockade (CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference,
Mainz/Frankfurt, Germany, 2017)
11. Oncolytic virotherapy with JX-594 (Pexa-Vec) modulates tumor immune microenvironment to potentiate
the efficacy of immune checkpoint blockade (Keystone symposia, Montreal, Canada, 2018)
12. Combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to
immunotherapy in renal cell carcinoma (AACR Annual Meeting, Chicago, United States, 2018)
13. STING signaling has a favorable clinical implication in colorectal cancer (CRI-CIMT-EATI-AACR
International Cancer Immunotherapy Conference, New York, United States, 2018)
14. Management of biliary cancer: metastatic disease (The 27th Clinical Trial Education Workshop, Seoul,
Korea, 2018)
15. An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune
checkpoint blockade (ESMO 2018, Munich, Germany)
16. STING, an immune biomarker for colorectal cancer (ESMO Asia 2018, Singapore)
17. Current evidence and future perspective of immunotherapy in HCC (HCC Symposium, KSMO, Seoul,
Korea, 2018)
▪ Patents
1. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy (PCT/US2018/028952, 2018)
2. Novel IDO/TDO inhibitors (62647483, 2018)
PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C.
CURRENT POSITION
Professor of Oncology, Pharmacology and Medicine
Kathryn Cramer Endowed Chair in Cancer Research
Vice President of Medical Affairs
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Office Address #1 Office Address #2
Karmanos Cancer Institute Karmanos Cancer Center at
4100 John R Street Farmington Hills (Weisberg)
Mail Code: HW04HO 31995 Northwestern Hwy.
Detroit, MI 48201 USA Farmington Hills, MI 48334
Phone: 1-313-576-8728 Phone: 1-248-538-4701
Fax: 1-313-576-8767
E-mail: [email protected]
Education Ph.D. in Clinical Pharmacology and Pharmacogenetics, University of London,
1982 - 1986
Guy’s Hospital Medical School, London, UK
M.D., University of Baghdad, College of Medicine, Baghdad, Iraq 1971 - 1977
Baccalaureate, Baghdad College, American Jesuit Fathers, Baghdad, Iraq 1965 – 1971
Post-Graduate Training
Fellowship Course in Leadership, Advisory Board Company, D.C.
2014 - 2015
Fellow in Medical Oncology, MD Anderson Cancer Center, Houston, Texas 1993 - 1995
Senior Registrar in Medical Oncology, University of Oxford and Imperial Cancer
Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, United Kingdom
1988 - 1993
Registrar in Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester,
University of Manchester, United Kingdom
1988 - 1988
Registrar in Medical Oncology, Charing Cross Hospital, University of London, London,
United Kingdom
1986 - 1988
Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology
and Lymphoma Unit, Guy's Hospital Medical School, University of London, London,
United Kingdom
1982 - 1986
Resident Medical Officer, St. Raphael Hospital, Baghdad, Iraq 1981 - 1982
Lecturer in Clinical Pharmacology, Baghdad University Medical College, Baghdad, Iraq 1981 - 1982
Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of 1980 - 1981
Baghdad, Iraq
Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq 1978-80
Intern in Internal Medicine and General Surgery, Medical City Teaching Hospital, 1977 - 1978
University of Baghdad, Baghdad, Iraq
Faculty Appointments
Professor in Pharmacology (secondary appointment) 2016 - present
Endowed Dr. Kathryn Cramer Professor of Cancer Research 2015 - present
Professor with Tenure, Department of Oncology with secondary appointment at Dept 2010 - present
of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI, USA
Professor with Tenure, Department of Internal Medicine, Wayne State University, 2006 - present
Detroit, MI
Clinical Professor in Oncology, Karmanos Cancer Institute, NCI-designated 2003 - 2006
Comprehensive Cancer Center, Detroit, MI
Professor (Clinician-Educator Track) in Internal Medicine, Wayne State University, 2003 - 2006
School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology,
Detroit, MI
Associate Professor in Oncology, Karmanos Cancer Institute, NCI-designated 1998 - 2003
Comprehensive Cancer Center Detroit, MI
Associate Professor (Clinician-Educator Track) in Medicine, Wayne State University, 1998 - 2003
School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology,
Detroit, MI
Assistant Professor (Clinician-Educator Track), Karmanos Cancer Institute, NCI- 1995 - 1998
designated Comprehensive Cancer Center, Wayne State University, School of Medicine,
Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI
Hospital or Other Professional Appointments
Chair, GI Committee, SWOG 2019 -
Vice President for Medical Affairs, Karmanos Cancer Hospital, Detroit 2012 - present
President of Medical Staff, Karmanos Cancer Hospital, Detroit 2010 - 2012
Leader of Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team 2006 - present
Attending Physician at Karmanos Cancer Hospital 2005 - present
Attending Physician in Hematology/Oncology at the Detroit Medical Center (DMC), 1995 - present
Detroit, MI. Privileges at Harper University Hospital, Detroit Receiving Hospital and
Hutzel Hospital
COMMITTEES
Member, Scientific Committee: ESMO 21st Annual World Congress on Gastrointestinal Cancer 2018 -
present
Member, Department of Oncology Review Committee, School of Medicine 2018
Member, P&T/Selective Salary Committee, Dept of Oncology 2016 - present Member, Metastatic Pancreatic Cancer Guideline Panel, ASCO 2018
Member, ACCC HCC Advisory Committee,
Member, Working Group, North America Neuroendocrine Tumors Society (NANETS),
Chair, Budget Advisory Committee, School of Medicine, WSU Leader of hepatopancreaticobiliary track and member of planning committee of
2018- present
2018 - present
2017 - present 2017 - present
ASCO GI Member, Recruitment and retention subcommittee, KCI
2017 - present
Poster Judging Panel for the Medical Student Research Symposium 2017
Abstract selection Committee, Annual NANET meeting 2017, 2018
Member, Promotion & Tenure Committee, WSU 2011, 2015-2017
Ad hoc external member, Promotions Committee, Harvard Medical School 2016
Member, Caris, Center of Excellence GI Tumor Group, 2016 -
Member, Policy Committee, KCC 2016 -
Member, Advisory Board, The Skyfoundation, Inc 2015 - present
Member of Planning Committee, led the Medical Oncology Working Group, 2015, 2017
Annual Karmanos Meeting Chair, Data Safety Monitoring Committee, Aslan Pharma
2017 –
Member, KCC Quality and Compliance Subcommittee, 2017 –
Member, Weisberg Expansion Committee, 2017 -
Member, Steering Committee, Phase III APACT Trial, 2015 -
Member, Physician Lab Advisory Council 2015
Member, Data Safety Monitoring Committee, Lexicon #1606.301-303 2016 -
Member, ad hoc, Dr Rosner PT Committee, Department of Dermatology and CMMG 2015 and 2016
Member, Organizing Committee, International GI Symposium, Turkey 2014 - present
Member, Hearing Panel, WSU 2014 - 2020
Member, Professionalism Committee, WSU 2014 - 2020
Member, KCI/McLaren Integration Steering Committee 2014 -present
Member, ASCO Metastatic Pancreas Cancer Guideline Committee 2014, 2018
Member, Editorial Board for “Together we’re better”, KCI/McLaren 2014 – present
Grant reviewer, Molecular Therapeutics Program 2014 – present
Member of GI/NET track, McLaren Medical Oncology Care Plans 2014 - present
Member, Hospitalist Liaison Committee 2014 – present
Member, Scientific Strategy Planning Retreat 5/5/2014
Member, International Pancreatic Cancer Forum 2014 - present
Member, Medical Advisory Board, Pancreatic Action Network (PanCan) 2012 - present
Chair, Clinic Improvement Initiative Working Group 2012 - present
Chair, Utilization Review Committee, KCC 2012 - present
Chair, HPIC, KCC 2012 - present
Member, Steering Committee, Molecular Therapeutics Program, KCI 2012 - present
Member, Executive Committee of the School of Medicine, Wayne State University 2011 – 2014
Department of Oncology P&T and Salary and Appointment Committee, Karmanos 2011 - present
Cancer Institute Co-Leader of the GI Subcommittee of the California NO1 Consortium
2011 - 2014
President, KCI Medical Executive Committee 2011 - 2012
Member, KCC Board of Directors 2010 - present
President Elect, Medical Staff Leadership Council, Karmanos Cancer Center 2008 - 2010
Chair, Protocol Review and Monitoring Committee 2003 - 2011
Member, IDEA (International Development and Education Award) through ASCO 2009 - 2014
Member, Executive Committee of the Faculty Senate, Wayne State University 2007 - 2010
Member, Chair of Pathology Search Committee, Dean’s Office, School of Medicine, 2007 - 2008
Wayne State University Member, Clinical Leadership Council, Karmanos Cancer Institute
2006 - present
Member, Financial Conflict of Interest Committee, Wayne State University 2006 - 2010
Leader, Organizing Committee, State of Science Meeting on Pancreas Cancer Sponsored by NCI (November 30th & December 1st, 2007)
2006 - 2007
Member, ASCO Educational Committee, Non-Colorectal GI 2005 - 2008
School of Medicine Committee to review the Department of Surgery 2005
Member, MD/PhD admission committee, School of Medicine, Wayne State University 2005
Member, CTEP site visit to New York University, Cancer Center 2004
Member of the Scientific Leadership Council, Karmanos Cancer Institute 2003 - 2011
Leader of Pancreas Cancer Subcommittee and member of the Steering Committee for GI 2000 - present
Cancer, Southwest Oncology Group (SWOG)
Member of the Intergroup Task Force on Pancreatic Cancer 2000 - present
Member, DMC Hematology/Oncology Pharmacy Therapeutics Subcommittee 1999 - 2002
Member, Fellows Education Committee, Oncology Fellowship Oncology Program, WSU 1999
Wertz Clinical Care Center Operational Focus Group, Karmanos Cancer Institute 1998
Member, Drug Development Program, Karmanos Cancer Institute 1997 - 2005
Member, Wertz Business/Clinical Audit Committee, Karmanos Cancer Institute 1997 - 2000
Member in the Protocol Review Committee, Karmanos Cancer Institute 1996 - 2003
Member, Primary Cancer Prevention Task Force, Karmanos Cancer Institute 1995 - 2000
Human Applications Group, Institute of Chemical Toxicology, Wayne State University 1995 - 2000
SERVICE
Patient Care
Medical Oncology – Karmanos Cancer Hospital, Harper University Hospital, Detroit In-Patients
Receiving Hospital, and Hutzel Hospital, Detroit, MI
Medical Oncology - Karmanos Cancer Hospital, Harper University Hospital, Detroit Consults
Receiving Hospital, and Hutzel Hospital, Detroit, MI
GI Multidisciplinary Program – One clinic/week (Monday) Outpatients
Farmington Karmanos Center Clinic - Two clinics/week (Tuesday/Wednesday)
Major Professional Societies
European Society of Medical Oncology (ESMO) 2017 -
International Liver Cancer Association (ILCA) 2010 - present
North America Neuroendocrine Tumor Society (NANET) 2015 -
American Pancreatic Association (APA) 2000 - present
American Society of Clinical Pharmacology and Therapeutics (ASCPT) 1998 - 2004
American College of Physicians (ACP) 1998 - 2000
NSABP 1998 - 2000
Society of Toxicology, Michigan Regional Chapter 1996 - 2004
Southwest Oncology Group (SWOG) 1995 - present
American Society of Clinical Oncology (ASCO) 1995 - present
American Association for Cancer Research (AACR) 1995 - present
Pharmacology and Molecular Mechanisms Group (PAMM) of the European 1990 - present
Organization for Research and Treatment of Cancer (EORTC)
Board Certifications
ABIM re-certification in Medical Oncology 2015 - 2025
ABIM certification in Medical Oncology 2005 – 2015
ABIM certification in Internal Medicine 2004 - 2014
Accreditation in the Subspecialty of Medical Oncology by the Joint Committee for 1991
Higher Medical Training of the United Kingdom and the Royal College of Physicians
of the UK
M.R.C.P. (Internal Medicine Diploma), Royal College of Physicians of the United 1985
Kingdom
Fellowship of the Royal College of Physicians (FRCP) of the UK
